drugset / Trial / NCT00441818
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lebrikizumab | Monoclonal antibody | — | — |